|Bid||14.41 x 1300|
|Ask||15.39 x 1200|
|Day's Range||14.58 - 15.36|
|52 Week Range||12.90 - 76.22|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 18, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.85|
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 22, 2022 / CureVac N. (Nasdaq:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's annual general meeting.
The big shareholder groups in CureVac N.V. ( NASDAQ:CVAC ) have power over the company. Insiders often own a large...
* Acquisition extends CureVac's capabilities and adds key competencies to further accelerate oncology strategy for new therapies that enable patients' immune systems to fight cancer * Frame's platform offers potential to develop off-the-shelf and personalized cancer vaccines targeting novel families of neoantigensTÜBINGEN, GERMANY and AMSTERDAM, NETHERLANDS / ACCESSWIRE / June 8, 2022 / CureVac N. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicine